Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP

NCT00418795 is registered in ClinicalTrials.gov with Zymenex A/S as lead sponsor.

NCT NCT00418795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00418795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP
Lead sponsor
Zymenex A/S
Phase
Phase 2/3
Overall status
Completed
Start date
June 11, 2003
Completion date
June 20, 2006
Enrollment
36
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute intermittent porphyria